No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes
- PMID: 20357369
- PMCID: PMC2890336
- DOI: 10.2337/dc09-2297
No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes
Abstract
Objective: To determine whether daily intake of 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is safe and improves beta-cell function in patients with recently diagnosed type 1 diabetes.
Research design and methods: Safety was assessed in an open study of 25 patients aged 18-39 years with recent-onset type 1 diabetes who received 0.25 microg 1,25(OH)(2)D(3) daily for 9 months. An additional 40 patients were randomly assigned to 0.25 microg 1,25(OH)(2)D(3) or placebo daily for 9 months and followed for a total of 18 months for safety, beta-cell function, insulin requirement, and glycemic control.
Results: Safety assessment showed values in the normal range in nearly all patients, regardless of whether they received 1,25(OH)(2)D(3) or placebo. No differences in AUC C-peptide, peak C-peptide, and fasting C-peptide after a mixed-meal tolerance test between the treatment and placebo groups were observed at 9 and 18 months after study entry, with approximately 40% loss for each parameter over the 18-month period. A1C and daily insulin requirement were similar between treatment and placebo groups throughout the study follow-up period.
Conclusions: Treatment with 1,25(OH)(2)D(3) at a daily dose of 0.25 microg was safe but did not reduce loss of beta-cell function.
Trial registration: ClinicalTrials.gov NCT00960635.
Figures



Similar articles
-
No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18. Diabetes Care. 2009. PMID: 19690081 Free PMC article. Clinical Trial.
-
The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).Diabet Med. 2006 Aug;23(8):920-3. doi: 10.1111/j.1464-5491.2006.01921.x. Diabet Med. 2006. PMID: 16911633 Clinical Trial.
-
Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).Diabetes Metab Res Rev. 2009 Jul;25(5):411-6. doi: 10.1002/dmrr.977. Diabetes Metab Res Rev. 2009. PMID: 19488999 Clinical Trial.
-
No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.Diabetes Care. 2010 Sep;33(9):1962-3. doi: 10.2337/dc10-0814. Diabetes Care. 2010. PMID: 20805274 Free PMC article. Clinical Trial.
-
A systematic review and meta-analysis of interventions to preserve insulin-secreting β-cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose control.Diabet Med. 2022 Jan;39(1):e14730. doi: 10.1111/dme.14730. Epub 2021 Nov 2. Diabet Med. 2022. PMID: 34676911
Cited by
-
Nutritional factors and preservation of C-peptide in youth with recently diagnosed type 1 diabetes: SEARCH Nutrition Ancillary Study.Diabetes Care. 2013 Jul;36(7):1842-50. doi: 10.2337/dc12-2084. Diabetes Care. 2013. PMID: 23801797 Free PMC article.
-
It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes.Diabetes. 2011 Feb;60(2):361-3. doi: 10.2337/db10-1506. Diabetes. 2011. PMID: 21270247 Free PMC article. No abstract available.
-
Treating vitamin D deficiency in children with type I diabetes could improve their glycaemic control.BMC Res Notes. 2017 Sep 7;10(1):465. doi: 10.1186/s13104-017-2794-3. BMC Res Notes. 2017. PMID: 28882195 Free PMC article.
-
Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes.PLoS One. 2013;8(2):e56488. doi: 10.1371/journal.pone.0056488. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437144 Free PMC article.
-
Risk factors and primary prevention trials for type 1 diabetes.Int J Biol Sci. 2013 Jul 18;9(7):666-79. doi: 10.7150/ijbs.6610. Print 2013. Int J Biol Sci. 2013. PMID: 23904791 Free PMC article. Review.
References
-
- Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221–229 - PubMed
-
- Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus. The Eurodiab Substudy 2 Study Group. Diabetologia 1999; 42: 51–54 - PubMed
-
- Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes; a birth-cohort study. Lancet 2001; 358: 1500–1503 - PubMed
-
- Zipitis CS, Akobeng AK: Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93: 512–517 - PubMed